JPS61502817A - Gel-containing pharmaceutical preparations - Google Patents
Gel-containing pharmaceutical preparationsInfo
- Publication number
- JPS61502817A JPS61502817A JP60503347A JP50334785A JPS61502817A JP S61502817 A JPS61502817 A JP S61502817A JP 60503347 A JP60503347 A JP 60503347A JP 50334785 A JP50334785 A JP 50334785A JP S61502817 A JPS61502817 A JP S61502817A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- active substance
- pluronic
- drug
- prostaglandin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Abstract
(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。 (57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】 ケ9ル含有製剤学的調製物 本発明は、治療及び診断の目的の新規ゲル処方物並びにこの処方物の製法に関す る。[Detailed description of the invention] Pharmaceutical preparations containing kelp The present invention relates to a novel gel formulation for therapeutic and diagnostic purposes and to a process for the preparation of this formulation. Ru.
西ドイツ特許出願公開(DE−○S)第3001454号明細書から、適用前に すぐ使える粘稠性溶液に変えられるプロスタグランジンを有するヒドロキシル基 含有ポリマーの凍結乾燥処方物(Lyophilisat −Formulie rungen)は公知である。この処方物の欠点は、作用物質の放出を困難にす るか又はむしろ阻止する小塊が生じることである。西ドイツ特許出願公開第33 07816号明細曹には、プロスタグランジンの水溶液が添加されるアルカリポ リアクリレートの凍結乾燥物が記載されている。この処方物からは、作用物質が 良好に放出されるが、相変らず、一様な高い粘度を有するこのようなゲル中への 作用物質の部・公的な不均質な導入及び特に使用者によるこのゲルの適用可能性 は不満足のまま残っている。本発明は、体腔内又は体表面で使用すべき限られた 安定性を有する作用物質に対するゲル処方物を開発することを課題とした。From West German Patent Application Publication (DE-○S) No. 3001454, before application Hydroxyl group with prostaglandins that can be converted into a ready-to-use viscous solution Freeze-dried formulations of containing polymers (Lyophilisat-Formulie rungen) is well known. The disadvantage of this formulation is that it makes the release of the active substance difficult. or rather, a blocking nodule may form. West German Patent Application Publication No. 33 No. 07816 specification soda contains an alkaline solution to which an aqueous solution of prostaglandin is added. A lyophilized product of lyacrylate is described. From this formulation, the active substance into such gels that are well released but still have a uniformly high viscosity. Part of the active substance: Public heterogeneous introduction and applicability of this gel, especially by the user remain unsatisfied. The present invention is limited to use within body cavities or on the body surface. The task was to develop gel formulations for active substances with stability.
カナダ特許(CA)第1072−413号〔デルヴエントー発行(Dervre nt−Publikations)第18422C/11〕には、体表面又は体 腔内での治療又は予防の用途のための医薬品の担持剤として、ポリオキシエチレ ンーポリオキシプロピレンーブロックコポリマーの使用可能性が記載されている 。デル分の重量チは15〜50%で挙げられる。有利な範囲は、30重量%の実 施例から由来し:水溶液中でプルロニック(Pluronic) F −127 20%及びプルロニックL44 10%である。Canadian Patent (CA) No. 1072-413 [Published by Dervre nt-Publications) No. 18422C/11], body surface or body Polyoxyethylene as a carrier for pharmaceuticals for intracavitary therapeutic or prophylactic applications. The possibility of using polyoxypropylene block copolymers is described. . The weight ratio of del content is 15 to 50%. An advantageous range is 30% by weight Derived from the example: Pluronic F-127 in aqueous solution 20% and Pluronic L44 10%.
プルロニックF−127調製物の使用に関する他の記載は、眼科学の実際に関し てのみ認められる(西ドイツ特許出願公開第2708152号明細書)。Other descriptions of the use of Pluronic F-127 preparations relate to ophthalmological practice. (West German Patent Application No. 2708152).
ところで、この処方物中で、プルロニックF−12718〜19重量%分が、体 腔内又は体表面でのプルロニックF−127ケ9ル処万物の治療及び診断の用途 にとって特に有利であることが判明した。水弁18〜19重量%のゾルロニツク F−127分を有するプルロニックF−127水溶液は、低い温度及び高い温度 で、易動性の低粘度の液体であり、中間温度(20〜50°C)でのみ、高粘稠 性デルを形成する。By the way, in this formulation, Pluronic F-12718-19% by weight is Treatment and diagnosis of Pluronic F-127 in the cavity or on the body surface It turned out to be particularly advantageous for Water valve 18-19% by weight Zorlonik Pluronic F-127 aqueous solution with F-127 min at low temperature and high temperature It is a mobile, low-viscosity liquid and only becomes highly viscous at intermediate temperatures (20-50°C). Form a sex del.
この可逆性のゾルーケ8ル特性は、溶解した作用物質を、容易に冷プルロニック F−127溶液中に均質に導入することを許容し、好適な適用系(例えばカテー テルホースを用いるスプレー)にするのを許容する。使用の間又は使用の直後に 、使用場所で高粘稠性ゲルが生じる。This reversible property makes it easy to transfer dissolved active ingredients to cold pluronic acid. F-127 in a suitable application system (e.g. catheter). (spray using a detergent hose) is allowed. During or immediately after use , resulting in a highly viscous gel at the point of use.
第1図には、種々の量のプルロニックF−127を有するプルロニックF−12 7溶液の温度に関係する粘度特性が図示されている。この図面から、体温範囲に 関する最適粘度は、プルロニックF−127分が18〜19重量%にある溶液で 達成される。20%のプルロニックF−127溶液は、作用物質を溶解するため には、18〜19%溶液よりも低(冷却すべきである。プルロニックF−127 の百分率分を温度と対比させた第2図は、同様に、18〜19チの範囲がガレヌ ス製剤にとって特に有利な範囲である理由を明らかにしている。プルロニックF −12718〜19チ分を有するすべての溶液は、37℃の体温範囲ではデルと して存在し、作用物質の溶解のためには17°Cより低く冷却すべきではない。FIG. 1 shows Pluronic F-12 with various amounts of Pluronic F-127. 7 The temperature-related viscosity properties of the solution are illustrated. From this drawing, the body temperature range The optimum viscosity for achieved. 20% Pluronic F-127 solution to dissolve the active substance should be cooled (lower than the 18-19% solution. Pluronic F-127 Figure 2, which compares the percentage of temperature with temperature, similarly shows that the range of 18 to 19 degrees The reason why this range is particularly advantageous for drug formulations is clarified. Pluronic F All solutions with -12718 to 19 min are below del in body temperature range of 37° It should not be cooled below 17°C in order to dissolve the active substance.
この粘度は回転粘度計〔)・−ヶ・ビスコテスター(Haake Viskot ester) VTO2) ?用いて測定した。This viscosity can be measured using a rotational viscometer (), a viscotester (Haake), or a viscotester (Haake). ester) VTO2)? It was measured using
本発明のゾルロニツクF−127処方物は、セルロース誘導体をペースとする従 来慣用のゲルに比べて、冷却状態の作用物質が特別な冷却なしに加工でき、プル ロニックF−127がそのデル特性を変えることなく滅菌することができ、ゾル ロニツクF−127溶i中の作用物質は短時間安定性を有するという利点を有す る。すべてのゾルロニツクF−127処方物は、冷却状態で容易に適用可能であ シ、その加温及びケ9ル形成の前に、強い帖模コントラストー付着物(SchL elmb:+utkontrast−Beschlag) f保址する。プ/L 70ニックF−127は、毒物学的に無害で、数時間後に体に吸収される良好な 粘膜認容性のケゞル形成剤である。Zorlonik F-127 formulations of the present invention are based on cellulose derivatives. Compared to conventional gels, the active substance in the cooled state can be processed without special cooling and Ronic F-127 can be sterilized without changing its del properties and the sol The active substance in Ronik F-127 solution has the advantage of short-term stability Ru. All Zollonik F-127 formulations can be easily applied in the cold state. However, prior to heating and keratin formation, a strong SchL contrast deposit (SchL elmb:+utkontrast-Beschlag) fKeep. P/L 70 Nick F-127 is a good drug that is toxicologically harmless and absorbed into the body after a few hours. It is a mucosal-acceptable cael-forming agent.
本発明は、治療の目的のプロスタグランジン、ステロイドホルモン、抗真菌剤及 び抗生物質を有するケゞル処方物及び診断の目的のレントケゝン造影剤、超音波 造影剤及び団、AR−造影剤を有子るケ゛ル処方物に関する。The present invention relates to prostaglandins, steroid hormones, antifungal agents and gel formulations with antibiotics and x-ray contrast agents for diagnostic purposes, ultrasound Contrast Agents and Groups, AR - Contains contrast agent-containing cell formulations.
本発明は、同様に、前記物質を有するケゞル処方物の製法に関する。The invention likewise relates to a method for producing a kel formulation containing said substances.
本発明によるケ゛ル処方物は、使用される作用物質に関して充分に公知の治療又 は診断に有効量の作用物質を含有する。場合によっては、この新規処方物にガレ ヌス製剤で公知かつ慣用の助剤を添加する。The gel formulation according to the invention can be used in well-known therapeutic or contains a diagnostically effective amount of the agent. In some cases, this new formulation may Auxiliary agents known and customary in Nuss formulations are added.
妊娠モルモットにおけるスルプロストン(Sulproston)(16−2エ ノキシ−プロスタグランジン−E2−メタンスルホンアミド)含有プルロニック F−127ケ9ルの腟内適用は、常に、子宮収縮の早期開始をもたらした。処理 動物の大多数は流産した。Sulprostone (16-2E) in pregnant guinea pigs Pluronic containing Noxy-prostaglandin-E2-methanesulfonamide) Intravaginal application of F-127K always resulted in an early onset of uterine contractions. process The majority of animals aborted.
次の実施例につき本発明全説明するが、本発明はこれにより限定されるものでは ない。The invention will be fully illustrated with reference to the following examples, but the invention is not limited thereto. do not have.
例1 プルロニックF−1271,9,9を約15°Cの温度で、水(注射用’) 6 .4 g中に完全に溶かす。io’cに冷却した溶液全孔幅1.2μmの膜フィ ルターを通して檜過し、10m1のバイアル中に充填し、オートクレーブ中12 0℃で20分間滅菌する。このフ0ルロニソクF−127溶液は8°Cより低い 温度で貯蔵する。作用物質を含有するすぐ使用できる処方物全製造するために、 水(注射用)2.0mlと共に作用物質16−フエ/キンプロスタグランジン− E2−メタンスルホンアミド100μgを有するアンプ0ルの内容物を取り、冷 却フ0ルロニツクF−127溶液を有するこのバイアル中に加える。短時間の振 動の後に、18°Cより高い温度でケ゛ル化する澄明な均質溶液が生じる。Example 1 Pluronic F-1271,9,9 at a temperature of about 15°C in water (for injection) 6 .. Completely dissolve in 4 g. The solution cooled to IO’C is a membrane fibril with a total pore width of 1.2 μm. Pass through a filter, fill into a 10ml vial, and autoclave for 12 hours. Sterilize for 20 minutes at 0°C. This Fluoronisoku F-127 solution has a temperature lower than 8°C. Store at temperature. To produce all ready-to-use formulations containing active substances, Active substance 16-hue/quinprostaglandin- with 2.0 ml of water (for injection) Take the contents of an amperage containing 100 μg of E2-methanesulfonamide and cool it. Add to this vial with the fluorinated Fluoronic F-127 solution. Shake for a short time After the reaction, a clear homogeneous solution is obtained which calcifies at temperatures above 18°C.
例2 脱鉱質水64.6.9を45〜50’Cに加温し、これに順次に、アミrトリソ ゞ工酸(A、m1dotrizoes:ff1ure) 29.9g1メグルミ ン(Meglumin) s、o 9、水酸化ナトリウム0.329及びジナト リウムメゾチー) 0.04 g’e導入し、温度(45〜50 ’C) k一 定に保持しながら溶解させる1、約10°Cに冷却した溶液中に、プルロニック F−12723,1gを装入し、時々攪拌しなからケゞル形成剤が完全に溶解す るまで冷蔵庫温度で貯蔵する。接遇の後に、18°Cより高い温度でデル化する 、澄明な無色〜淡黄色溶液が生じる。Example 2 Demineralized water 64.6.9 is heated to 45-50'C and this is sequentially added to Acid (A, mldotrizoes: ff1ure) 29.9g 1 megurumi Meglumin s, o 9, sodium hydroxide 0.329 and dinate lium mesochi) 0.04 g’e was introduced, and the temperature (45-50’C) k- 1. Dissolve Pluronic in a solution cooled to about 10°C. Charge 1 g of F-12723 and stir occasionally until the cale forming agent is completely dissolved. Store at refrigerator temperature until cold. After treatment, delirate at a temperature higher than 18°C. , a clear colorless to pale yellow solution results.
第1図は種々の百分率のプルロニックF−127分金有するプルロニックF−1 27溶液の粘度と温度及び濃度との関係全示す図である。Figure 1 shows Pluronic F-1 with various percentages of Pluronic F-127 gold. FIG. 27 is a diagram showing the entire relationship between the viscosity, temperature, and concentration of the No. 27 solution.
第2図はプルロニックF−127溶液のデル−ゾル状態を示す図である。FIG. 2 is a diagram showing the del-sol state of Pluronic F-127 solution.
唄 国際調査報告 PCT/DE85700:37++wm−h−一一一−――Il a、PCT/DE85100二37AJ◇JEX To T!!五 INTER )IATIONAL 5EARCHREPORT 0NFR−A−240090 323103/79 NoneCA−A−107241326102/80 N oneINTERNATIONAL A、PPLZCATION No、 PC T/DE 85100237 (SA 10196)song International Search Report PCT/DE85700:37++wm-h-111---Il a, PCT/DE85100237AJ◇JEX To T! ! 5 INTER )IATIONAL 5EARCHREPORT 0NFR-A-240090 323103/79 NoneCA-A-107241326102/80N one INTERNATIONAL A, PPLZCATION No, PC T/DE 85100237 (SA 10196)
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3428264.5 | 1984-07-27 | ||
DE19843428264 DE3428264A1 (en) | 1984-07-27 | 1984-07-27 | VALID PHARMACEUTICAL PREPARATIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS61502817A true JPS61502817A (en) | 1986-12-04 |
Family
ID=6242046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60503347A Pending JPS61502817A (en) | 1984-07-27 | 1985-07-18 | Gel-containing pharmaceutical preparations |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0227656A1 (en) |
JP (1) | JPS61502817A (en) |
AU (1) | AU4672385A (en) |
DE (1) | DE3428264A1 (en) |
DK (1) | DK111686D0 (en) |
ES (1) | ES8705763A1 (en) |
IL (1) | IL75921A0 (en) |
WO (1) | WO1986000813A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012576A1 (en) * | 1989-04-25 | 1990-11-01 | The Green Cross Corporation | Liquid prostaglandin composition |
JPH07309782A (en) * | 1994-01-24 | 1995-11-28 | Takahiro Ogawa | Contrast medium |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0386960A3 (en) * | 1989-03-07 | 1991-10-23 | American Cyanamid Company | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings |
CA2040460C (en) * | 1990-05-01 | 1997-06-10 | Tacey X. Viegas | Drug delivery with thermoreversible gels |
US5593683A (en) * | 1990-05-01 | 1997-01-14 | Mdv Technologies, Inc. | Method of making thermoreversible polyoxyalkylene gels |
US5948387A (en) * | 1990-06-01 | 1999-09-07 | Imarx Pharmaceutical Corp. | Contrast media for ultrasonic imaging |
AU6956494A (en) * | 1993-06-04 | 1995-01-03 | Warner-Lambert Company | Non-alcoholic cold and sinus medication |
US6312666B1 (en) * | 1998-11-12 | 2001-11-06 | 3M Innovative Properties Company | Methods of whitening teeth |
US6312667B1 (en) | 1998-11-12 | 2001-11-06 | 3M Innovative Properties Company | Methods of etching hard tissue in the oral environment |
US6669927B2 (en) | 1998-11-12 | 2003-12-30 | 3M Innovative Properties Company | Dental compositions |
US6620405B2 (en) | 2001-11-01 | 2003-09-16 | 3M Innovative Properties Company | Delivery of hydrogel compositions as a fine mist |
EP3790597A4 (en) * | 2018-07-12 | 2022-03-09 | Arshintseva, Elena Valentinovna | Thermal method for sterilizing poloxamer comprising liquid drugs |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3867521A (en) * | 1970-08-26 | 1975-02-18 | Scherer Corp R P | Method for absorption of drugs |
US3852210A (en) * | 1972-08-11 | 1974-12-03 | Flow Pharma Inc | Stable liquid detergent concentrates containing active oxygen |
CA1051776A (en) * | 1974-08-09 | 1979-04-03 | Murray W. Winicov | Poloxamer-iodine gel |
US4100271A (en) * | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
CA1072413A (en) * | 1976-07-13 | 1980-02-26 | West Laboratories | Poloxamer gel systems with gelling temperatures higher than room temperature |
US4365516A (en) * | 1978-01-06 | 1982-12-28 | Rockwell International Corporation | Ultrasonic couplant gel compositions and method for employing same |
EP0012926B1 (en) * | 1978-12-19 | 1984-03-07 | Byk Gulden Lomberg Chemische Fabrik GmbH | Solutions of x-ray contrast agents |
SE431821B (en) * | 1979-01-29 | 1984-03-05 | Perstorp Ab | STORAGE STABLE, PROSTAGLANDIN-CONTAINING MEDICAL PREPARATION |
-
1984
- 1984-07-27 DE DE19843428264 patent/DE3428264A1/en not_active Withdrawn
-
1985
- 1985-07-18 EP EP85903649A patent/EP0227656A1/en not_active Withdrawn
- 1985-07-18 WO PCT/DE1985/000237 patent/WO1986000813A1/en not_active Application Discontinuation
- 1985-07-18 JP JP60503347A patent/JPS61502817A/en active Pending
- 1985-07-18 AU AU46723/85A patent/AU4672385A/en not_active Abandoned
- 1985-07-26 IL IL75921A patent/IL75921A0/en unknown
- 1985-07-26 ES ES545616A patent/ES8705763A1/en not_active Expired
-
1986
- 1986-03-11 DK DK111686A patent/DK111686D0/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012576A1 (en) * | 1989-04-25 | 1990-11-01 | The Green Cross Corporation | Liquid prostaglandin composition |
JPH07309782A (en) * | 1994-01-24 | 1995-11-28 | Takahiro Ogawa | Contrast medium |
Also Published As
Publication number | Publication date |
---|---|
WO1986000813A1 (en) | 1986-02-13 |
AU4672385A (en) | 1986-02-25 |
EP0227656A1 (en) | 1987-07-08 |
IL75921A0 (en) | 1985-12-31 |
ES545616A0 (en) | 1987-06-01 |
DK111686A (en) | 1986-03-11 |
DE3428264A1 (en) | 1986-03-06 |
ES8705763A1 (en) | 1987-06-01 |
DK111686D0 (en) | 1986-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0946143B1 (en) | A nitroimidazole gel composition | |
FI103714B (en) | Gel-forming liquid medium composition | |
JP4555402B2 (en) | Hemorrhoid composition and method of use | |
US5071644A (en) | Topical drug delivery with thermo-irreversible gels | |
US4888168A (en) | Stable ophthalmic preparations containing acetazolamide | |
JPS62190119A (en) | Medicine for high viscosity hydrogel or suspension | |
US5847023A (en) | Thermal irreversible gel corneal contact lens formed in situ | |
JPS61502817A (en) | Gel-containing pharmaceutical preparations | |
US5376693A (en) | Thermo-irreversible gel corneal contact lens formed in situ | |
JPH02300114A (en) | Remedy transmitting composite and trauma bandage composite | |
EA015356B1 (en) | Methods for the treatment of endometriosis | |
JPH08253412A (en) | Gelling agent for polyethylene glycol | |
SE431821B (en) | STORAGE STABLE, PROSTAGLANDIN-CONTAINING MEDICAL PREPARATION | |
JP4449213B2 (en) | Suppository composition | |
CN102525884A (en) | Thermosensitive in-situ gel preparation for vaginal administration | |
EP0089768A1 (en) | Compositions containing prostaglandins | |
US2477080A (en) | Antacid preparation | |
US6436425B1 (en) | Method and non-gelling composition for inhibiting post-surgical adhesions | |
JPS5931714A (en) | Contraceptive composition | |
KR102089117B1 (en) | Pharmaceutical compositions containing oligomeric lactic acid | |
JPS63166832A (en) | Solution for nose | |
CN103156805A (en) | Ciprofloxacin thermo-sensitive type in-situ gel composition and preparing method thereof | |
JP7454288B2 (en) | Method for preparing a novel veterinary uterine injection | |
JPH04502004A (en) | Preparations of oxypurinol and/or its alkali and alkaline earth salts | |
KR20210099553A (en) | Injectable sustained-release antibiotics |